TerrAscend (TSNDF) Liabilities and Shareholders Equity (2021 - 2026)
TerrAscend (TSNDF) posted quarterly Liabilities and Shareholders Equity of $549.1 million for Q1 2026, down 8.6% year-over-year from $600.7 million in Q1 2025, and down 1.49% quarter-over-quarter from $557.4 million in Q4 2025.
TerrAscend (TSNDF) Liabilities and Shareholders Equity (2021 - 2026) Analysis & Trends
TerrAscend (TSNDF) has reported Liabilities and Shareholders Equity for 6 consecutive years, with $549.1 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Liabilities and Shareholders Equity fell 8.6% year-over-year to $549.1 million; the TTM figure through Mar 2026 stood at $2.2 billion (down 11.54% YoY), while the FY2025 annual figure was $557.4 million, down 8.21% from the prior year.
- Liabilities and Shareholders Equity declined to $549.1 million in Q1 2026 per TSNDF's latest filing, from $557.4 million in the prior quarter.
- Across five years, Liabilities and Shareholders Equity topped out at $1.0 billion in Q1 2022 and bottomed at $91000.0 in Q2 2023.
- Historically, Liabilities and Shareholders Equity has averaged $646.4 million across 5 years, with a median of $656.9 million in 2024.
- Annual changes were most pronounced in 2023 — Liabilities and Shareholders Equity slumped 99.99% — and 2024, when it soared 725442.86%.
- TerrAscend's Liabilities and Shareholders Equity stood at $701.6 million in 2022, then decreased by 5.0% to $666.5 million in 2023, then decreased by 8.9% to $607.2 million in 2024, then fell by 8.21% to $557.4 million in 2025, then dropped by 1.49% to $549.1 million in 2026.
- Business Quant data shows TSNDF's Liabilities and Shareholders Equity at $549.1 million in Q1 2026, $557.4 million in Q4 2025, and $555.3 million in Q3 2025.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Liabilities and Shareholders Equity (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 43.83 Bn | 42.86 Bn | - | 43.71 Bn |
| 2 | Teva Pharmaceutical Industries | 42.87 Bn | 39.22 Bn | 2.15 Bn | 39.86 Bn |
| 3 | Zoetis | 31.41 Bn | 29.73 Bn | 1.05 Bn | 15.08 Bn |
| 4 | Takeda Pharmaceutical | 28.55 Bn | 22.75 Bn | 5.10 Bn | 98.27 Bn |
| 5 | United Therapeutics | 22.08 Bn | 19.42 Bn | 683.80 Mn | 7.22 Bn |
| 6 | Viatris | 18.73 Bn | 17.84 Bn | 1.46 Bn | 35.04 Bn |
| 7 | Neurocrine Biosciences | 15.44 Bn | 15.05 Bn | 935.80 Mn | 5.36 Bn |
| 8 | Elanco Animal Health | 11.75 Bn | 11.22 Bn | 798.00 Mn | 13.56 Bn |
| 9 | Dr Reddys Laboratories | 10.11 Bn | 9.94 Bn | - | 6.18 Bn |
| 10 | TerrAscend | 182.53 Mn | 140.41 Mn | 36.25 Mn | 553.71 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 553.71 Mn |
| Mar 31, 2026 | 549.10 Mn |
| Dec 31, 2025 | 557.38 Mn |
| Sep 30, 2025 | 555.26 Mn |
| Jun 30, 2025 | 572.01 Mn |
| Mar 31, 2025 | 600.73 Mn |
| Dec 31, 2024 | 607.23 Mn |
| Sep 30, 2024 | 656.93 Mn |
| Jun 30, 2024 | 660.24 Mn |
| Mar 31, 2024 | 655.54 Mn |
| Dec 31, 2023 | 666.52 Mn |
| Sep 30, 2023 | 734.67 Mn |
| Jun 30, 2023 | 91,000.00 |
| Mar 31, 2023 | 701.58 Mn |
| Dec 31, 2022 | 701.59 Mn |
| Sep 30, 2022 | 725.49 Mn |
| Jun 30, 2022 | 1.01 Bn |
| Mar 31, 2022 | 1.04 Bn |
| Dec 31, 2021 | 581.94 Mn |